MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$2,231,721
Unit: Dollar
Positive Cash Flow Breakdown
Prepaid and other assets
Amortization of capitalized shar...
Share-based compensation under e...
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued lia...
Accounts receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,265,586
-2,090,155
-1,439,058
-2,317,036
Depreciation
16,951
16,700
15,169
12,225
Amortization
13,860
9,165
8,398
10,605
Amortization of rou asset
-
-
0
0
Amortization of capitalized share-based payments
51,427
44,578
44,118
44,118
Share-based compensation under equity incentive plan
46,978
79,524
67,843
34,882
Change in fair value of derivative liabilities
-5,665
-4,567
422,534
-21,103
Write-offs of capitalized patents
-
-
0
0
Change in inventory reserve
0
-251,677
6,995
244,682
Accounts receivable
231,204
-173,808
-164,392
379,002
Prepaid and other assets
-361,137
742,717
29,859
253,538
Inventory
-32,658
2,002
136,915
-27,735
Accounts payable and accrued liabilities
-262,817
11,735
35,705
445,639
Accrued interest, net
790
-4,915
6,710
485
Reduction of lease liability
-
-
0
0
Net cash used in operating activities
-2,231,721
-2,741,559
-1,692,456
-2,109,072
Capitalization of patents
33,048
0
34,665
13,703
Purchases of fixed assets
0
30,000
79,881
9,999
Acquisition of intangibles
52,936
11,440
20,885
1,785
Purchase of short-term investments
-
-
1,235,000
0
Maturities of short-term investments
0
1,235,000
0
0
Net cash provided by investing activities
-85,984
1,193,560
-1,370,431
-25,487
Net proceeds from january 2024 offering
-
-
0
0
Net proceeds from atm offering
0
3,369,752
458,614
0
Net proceeds from january 2025 offering
0
0
0
0
Net proceeds from february 2025 offering
0
0
0
0
Net proceeds from july 2025 offering
-
-
0
4,281,300
Net proceeds from private placement
-
-
0
0
Shares withheld for net share settlement of performance bonuses
0
0
0
0
Proceeds from exercise of pre-funded warrants
0
0
0
878
Net cash provided by financing activities
0
3,369,752
458,614
4,282,178
Effect of exchange rate changes on cash
2,551
5,942
-1,441
1,230
Change in cash and cash equivalents
-2,315,154
1,827,695
-2,605,714
2,148,849
Cash and cash equivalentsbeginning of period
3,337,760
1,510,065
4,115,779
1,659,353
Cash and cash equivalentsend of period
1,022,606
3,337,760
1,510,065
4,115,779
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Effect of exchange rate
changes on cash
$2,551
(-65.24%↓ Y/Y)
Change in cash and cash
equivalents
-$2,315,154
(-852.71%↓ Y/Y)
Canceled cashflow
$2,551
Prepaid and other assets
-$361,137
(-36.84%↓ Y/Y)
Amortization of capitalized
share-based payments
$51,427
(-41.72%↓ Y/Y)
Share-based compensation
under equity...
$46,978
(-73.48%↓ Y/Y)
Inventory
-$32,658
(-109.16%↓ Y/Y)
Depreciation
$16,951
(6.41%↑ Y/Y)
Amortization
$13,860
(-32.54%↓ Y/Y)
Change in fair value of
derivative liabilities
-$5,665
(95.81%↑ Y/Y)
Net cash used in
operating activities
-$2,231,721
(26.77%↑ Y/Y)
Net cash provided by
investing activities
-$85,984
(-105.21%↓ Y/Y)
Canceled cashflow
$528,676
Net loss
-$2,265,586
(37.28%↑ Y/Y)
Acquisition of intangibles
$52,936
Capitalization of patents
$33,048
(361.24%↑ Y/Y)
Accounts payable and
accrued liabilities
-$262,817
(-2798.60%↓ Y/Y)
Accounts receivable
$231,204
(220.60%↑ Y/Y)
Accrued interest, net
$790
(104.20%↑ Y/Y)
Buy us a coffee
60 DEGREES PHARMACEUTICALS, INC. (SXTP)
60 DEGREES PHARMACEUTICALS, INC. (SXTP)